Quebec implements public reimbursement of Pluvicto® – a defining milestone for radioligand therapy in Canada
— Pluvicto® now publicly funded in provinces covering most Canadians, offering renewed hope to those facing progressive PSMA-positive metastatic castration-resistant prostate cancer — Momentum builds nationwide as more jurisdictions recognize radioligand as a critical therapy for advanced prostate cancer Novartis Pharmaceuticals Canada Inc. (Novartis) is pleased to announce that, as of July 2, 2025, Pluvicto®(lutetium […]